EUVIMEDAtrasti EUVIMED
Crossref

Optimizing VCTE and ELF Thresholds for Treatment‐Eligible F2–F3 Fibrosis in Japanese Patients With MASLD

Yuya Seko iD, Taeang Arai iD, Hirokazu Takahashi iD, Hidenori Toyoda iD, Hideki Hayashi, Kanji Yamaguchi, Michihiro Iwaki iD, Masato Yoneda, Toshihide Shima, Hideki Fujii iD, Asahiro Morishita iD, Kazuhito Kawata iD and 14 more

Hepatology Research · 2026-06 · 56 (6) · 1007-1015

DOI: 10.1111/hepr.70155 ↗

At a glance

Journal article in Hepatology Research, published online on 2026-03-12. Written by Yuya Seko and 25 co-authors. Institution: Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Cited 1 times so far (Crossref); 21 references.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Aim

To assess whether non‐invasive test cutoffs recommended in Western guidelines appropriately identify treatment‐eligible fibrosis (F2–3) in Japanese patients with MASLD.

Methods

We analyzed Japanese patients with biopsy‐proven MASLD who underwent FIB‐4 screening, followed by VCTE or ELF testing. Patients with FIB‐4 < 1.3 at age < 65 years or < 2.0 at age ≥ 65 years were excluded, leaving 838 patients in the VCTE cohort and 657 in the ELF cohort. Receiver operating characteristic (ROC) analyses were used to derive cohort‐specific cutoffs.

Results

For predicting F2–4, a VCTE cutoff of 8 kPa yielded sensitivity/specificity/positive predictive value (PPV)/negative predictive value (NPV) of 83.7%/61.2%/80.2%/66.7%. For predicting F4, a VCTE cutoff of 15 kPa yielded 88.1%/76.8%/22.3%/98.8%. For ELF, a cutoff of 9.2 for predicting F2–4 yielded 94.7%/23.1%/66.5%/73.1%. For predicting F4, a ELF cutoff of 10.5 yielded 80.0%/58.4%/9.9%/98.1%. Using ROC‐derived cutoffs (VCTE 9.5 and 15 kPa; ELF 10.3 and 10.8), the performance for predicting F2–4 was 74.0%/75.6%/85.1%/60.8% for VCTE and 66.2%/73.9%/80.6%/57.1% for ELF, whereas the performance for predicting F4 was 88.1%/76.8%/22.3%/98.8% for VCTE and 77.1%/69.8%/12.6%/98.2% for ELF. Among test‐positive patients, the distribution of F0–1/F2–3/F4 was 28.7%/69.2%/2.1% for VCTE 8–15 kPa and 47.8%/49.8%/2.4% for ELF 9.2–10.5.

Conclusions

Western guideline‐recommended VCTE and ELF cutoffs showed high sensitivity in Japanese patients and can be used to exclude cirrhosis. Because the likelihood of cirrhosis increases with VCTE > 15 kPa or ELF > 10.5, treatment eligibility should be determined in conjunction with other clinical information, and confirmatory assessment should be considered when appropriate.

Subjects

Author keywords

ELFMASLDVCTEliver fibrosis

Authors and institutions

  • Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Liver Center, Saga University Hospital, Saga, Japan.
  • Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
  • Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

ORCID profiles: Yuya Seko, Taeang Arai, Hirokazu Takahashi, Hidenori Toyoda, Michihiro Iwaki, Hideki Fujii, Asahiro Morishita, Kazuhito Kawata, Tadashi Ikegami, Satoshi Oeda, Masanori Atsukawa, Yoshihiro Kamada, Shinichi Aishima, Tomohisa Takagi, Atsushi Nakajima

Cite

APA

Seko, Y., Arai, T., Takahashi, H., Toyoda, H., Hayashi, H., Yamaguchi, K., Iwaki, M., Yoneda, M., Shima, T., Fujii, H., Morishita, A., Kawata, K., Tomita, K., Kawanaka, M., Yoshida, Y., Ikegami, T., Notsumata, K., Oeda, S., Atsukawa, M., …, & Nakajima, A. (2026). Optimizing VCTE and ELF Thresholds for Treatment‐Eligible F2–F3 Fibrosis in Japanese Patients With MASLD. Hepatology Research, 56(6), 1007-1015. https://doi.org/10.1111/hepr.70155

Vancouver

Seko Y, Arai T, Takahashi H, Toyoda H, Hayashi H, Yamaguchi K, et al. Optimizing VCTE and ELF Thresholds for Treatment‐Eligible F2–F3 Fibrosis in Japanese Patients With MASLD. Hepatology Research. 2026;56(6):1007-1015. doi:10.1111/hepr.70155

BibTeX
@article{Seko2026,
  author = {Seko, Yuya and Arai, Taeang and Takahashi, Hirokazu and Toyoda, Hidenori and Hayashi, Hideki and Yamaguchi, Kanji and Iwaki, Michihiro and Yoneda, Masato and Shima, Toshihide and Fujii, Hideki and Morishita, Asahiro and Kawata, Kazuhito and Tomita, Kengo and Kawanaka, Miwa and Yoshida, Yuichi and Ikegami, Tadashi and Notsumata, Kazuo and Oeda, Satoshi and Atsukawa, Masanori and Kamada, Yoshihiro and Sumida, Yoshio and Miyoshi, Eiji and Aishima, Shinichi and Okanoue, Takeshi and Takagi, Tomohisa and Nakajima, Atsushi},
  title = {Optimizing VCTE and ELF Thresholds for Treatment‐Eligible F2–F3 Fibrosis in Japanese Patients With MASLD},
  journal = {Hepatology Research},
  year = {2026},
  volume = {56},
  number = {6},
  pages = {1007--1015},
  doi = {10.1111/hepr.70155}
}
Start for free →